ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1707

Exploring the Role of Lipocalin-2 in Neuropsychiatric SLE

Chaim Putterman1, Sayra Garcia-Murillo2 and Elise Mike3, 1Albert Einstein College of Medicine, Bronx, NY, 2Albert Einstein College of Medicine, New York, NY, 3John Hopkins University, Baltimore, MD

Meeting: ACR Convergence 2022

Keywords: Mouse Models, Lupus, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2022

Title: SLE – Animal Models Poster

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: While the etiology of neuropsychiatric lupus (NPSLE) is not fully understood, blood brain barrier (BBB) disruption and localized neuroinflammation are potential mechanisms that contribute to disease progression. Lipocalin-2 (LCN2) is a multi-functional acute phase protein known to affect immune cell function, BBB integrity, and glial cell activation. The MRL/lpr mouse strain not only captures multiple human facets of SLE such as female predominance, nephritis, and cutaneous disease, it is the mostly widely used NPSLE model. Displaying cognitive deficits and depression-like behavior at an early age, the MRL/lpr mouse is an important model for studying NPSLE disease mechanisms. We generated an LCN2-deficient MRL/lpr mouse and examined the effects of LCN2 deficiency on neurobehavioral parameters, uncovering a role of LCN2 in cognitive and affective deficits in the MRL/lpr strain.

Methods: Behavioral assessment was performed on LCN2 deficient MRL/lpr mice (LCN2KO), MRL/lpr LCN2 sufficient mice, and MRL/MpJ mice at 16 weeks of age. The tests performed include the behavioral spectrometer, anhedonia, tail suspension, Porsolt forced swim, object placement, and object recognition tests. The mice were sacrificed promptly after completion of the neurobehavioral assessments and tissues were either snap frozen for RNA and protein studies, or fixed in paraformaldehyde for immunofluorescent staining. Systemic disease was evaluated through monitoring anti-nuclear antibodies, total IgG levels, and kidney disease, and as well as lymph node size and the severity of skin disease. To evaluate how LCN2 deficiency affects brain inflammation, 10 week old LCN2KO and MRL/lpr mice were injected intraperitoneally with 5 mg/kg lipopolysaccharide. The mice were then sacrificed, perfused, and the brains were fixed and paraffin-embedded for immunofluorescent staining. Brain tissue was stained for infiltrating leukocytes as well as glial cells and LCN2 protein.

Results: We found that LCN2 deficiency in MRL/lpr mice did not affect serum anti-nuclear antibody, serum IgG, or proteinuria as shown by ELISA. However, cutaneous disease was significantly improved in LCN2-deficient MRL/lpr mice (Figure 1). The behavioral analyses additionally showed significant improvement in LCN2 deficient mice, in the tail suspension (not shown), Porsolt forced swim, and object placement tests (Figure 2). Finally, following an inflammatory stimulus, LCN2 deficiency resulted in significantly decreased activation of astrocytes in the hippocampus, a brain region involved in emotionality and cognitive function.

Conclusion: Our results point to an important role of LCN2 in perpetuating local brain inflammation, that may contribute to depression and cognitive deficits in MRL/lpr mice. LCN2 deficiency not only improves the NPSLE phenotype in this strain, but also decreases local brain inflammation. Since kidney disease and serologic features were largely unaffected, it is likely that LCN2 plays a role more locally in the brain, suggesting LCN2 as a potential target for the treatment of NPSLE in patients who do not successfully respond to traditional therapies for diffuse disease.

Supporting image 1

Supporting image 2


Disclosures: C. Putterman, Equillium, Progentec, Kidneycure; S. Garcia-Murillo, None; E. Mike, None.

To cite this abstract in AMA style:

Putterman C, Garcia-Murillo S, Mike E. Exploring the Role of Lipocalin-2 in Neuropsychiatric SLE [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/exploring-the-role-of-lipocalin-2-in-neuropsychiatric-sle/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/exploring-the-role-of-lipocalin-2-in-neuropsychiatric-sle/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology